FACET BIOTECH CORP Form S-8 POS April 21, 2010

As filed with the Securities and Exchange Commission on April 21, 2010

Post-Effective Amendment No. 1 to Registration No. 333-156816

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Facet Biotech Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or

26-3070657 (I.R.S. employer identification no.)

organization)

1500 3	Seaport	Boule	vard
--------	---------	-------	------

Redwood	City	$C\Delta$	94063
Neuwoou	CILY,	$\mathbf{c}_{\mathbf{A}}$	77 003

(Address, including zip code of registrant s principal executive offices)

Facet Biotech Corporation 2008 Equity Incentive Plan

Facet Biotech Corporation 2008 Employee Stock Purchase Plan

(Full title of the plans)

Faheem Hasnain

Chief Executive Officer Facet Biotech Corporation 1500 Seaport Boulevard Redwood City, CA 94063

(Name and address of agent for service)

(650) 454-1000

(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act (Check one):

terated files and large decelerated files. In real 120 2 of the Exchange files (Check one).

Large accelerated filer o

Accelerated filer x

Non-accelerated filer o

Smaller reporting company o

(Do not check if a smaller

reporting company)

EXPLANATORY NOTE: DEREGISTRATION OF SECURITIES

On January 20, 2009, Facet Biotech Corporation, a Delaware corporation (the Company), filed a registration statement on Form S-8 (No. 333-156816) (the Registration Statement), which registered 5,056,054 shares of common stock of the Company, par value \$0.01 per share (the Common Stock), of which 4,456,054 shares of Common Stock were to be offered or sold under the Facet Biotech Corporation 2008 Equity Incentive Plan and 600,000 shares of Common Stock were to be offered or sold under the Facet Biotech Corporation 2008 Employee Stock Purchase Plan (together, the Plans).

On April 21, 2010 (the Effective Date), pursuant to an Agreement and Plan of Merger, dated as of March 9, 2010 (the Merger Agreement), among the Company, Abbott Laboratories, an Illinois corporation (Abbott), and Amber Acquisition Inc., a Delaware corporation and wholly owned subsidiary of Abbott (Merger Sub), Merger Sub merged with and into the Company, and the Company became a wholly owned subsidiary of Abbott (the Merger). In the Merger, each outstanding share of Common Stock (other than shares owned by the Company, any wholly owned subsidiary of the Company, Abbott or Merger Sub, and shares held by dissenting stockholders who properly exercise appraisal rights under Delaware law) was automatically converted into the right to receive \$27.00 in cash, without interest and subject to any required withholding taxes.

As a result of the Merger, the Company has terminated all offerings of the Company s securities pursuant to the Registration Statement. Accordingly, pursuant to the undertaking contained in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering, the Company is filing this Post-Effective Amendment No. 1 to the Registration Statement to deregister all the shares of Common Stock reserved for issuance under the Plans that remain unissued on the Effective Date.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on April 21, 2010.

Facet Biotech Corporation

By: /s/ Faheem Hasnain

Faheem Hasnain

President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities indicated on April 21, 2010.

Title Signature President and Chief Executive Officer (Principal Executive Officer) and /s/ Faheem Hasnain Director Faheem Hasnain Senior Vice President and Chief Financial Officer (Principal Financial /s/ Andrew Guggenhime Officer) Andrew Guggenhime /s/ Herb Cross Vice President, Finance (Principal Accounting Officer) Herb Cross /s/ Thomas C. Freyman Director Thomas C. Freyman 3